Last reviewed · How we verify
Complex dyslipidemia
Approved treatments
- Praluent · Sanofi
Praluent blocks the PCSK9 protein, which helps remove LDL cholesterol from the bloodstream, thereby reducing cholesterol levels. - Praluent · Regeneron Pharmaceuticals
- Repatha · Repatha
Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Complex dyslipidemia patent landscape — cliff calendar, originator estates, attackable patents
- Complex dyslipidemia treatment landscape brief
- Complex dyslipidemia treatment updates RSS
Frequently asked questions about Complex dyslipidemia
What drugs treat Complex dyslipidemia?
Tracked treatments include Praluent, Repatha.
What is the treatment for Complex dyslipidemia?
Standard treatment for Complex dyslipidemia includes Praluent, Repatha. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Complex dyslipidemia patent cliff · Complex dyslipidemia CI report
- Treatment: Praluent · Sanofi
- Treatment: Praluent · Regeneron Pharmaceuticals
- Treatment: Repatha · Repatha
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing